Official Patient Site | SPINRAZA® (nusinersen)

For the 10,000+ people
who have been treated with
SPINRAZA worldwide,*
victories are personal.

*Based on commercial patients, early access patients, and clinical trial participants through December 2019.

Discover SPINRAZA: the first FDA-
approved treatment for SMA

6+ years

Safety and efficacy
evaluated
in the longest
clinical trial in
SMA to date

3x/year

SPINRAZA is delivered directly to

the central nervous system (CNS)
where
motor neuron loss begins.
After
initial loading doses,
SPINRAZA is
given 3 times a year.

an adult with later-onset SMA who is being treated with SPINRAZA

From 3 days^† to 80 years old^‡§

There’s someone from almost every age group who has been treated with SPINRAZA.

Watch some of their stories

^†Includes clinical trial patients.

^‡Clinical studies of SPINRAZA did not include sufficient numbers of subjects aged 65 and older to determine
whether they respond differently from younger patients.

^§Based on commercial patients in the US (including Puerto
Rico) through December 2019.

Demonstrated efficacy in people with early and later-onset SMA

See the data

a child with later-onset SMA who is being treated with SPINRAZA

Safety & side effects

The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA.

See safety profile